Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Gibco™ Human IL-5, Animal-Free Recombinant Protein, PeproTech®

Click to view available options
Quantity:
1 mg
10 μg
100 μg
500 μg
Description
Recombinant Human IL-5 is a 26.5 kDa disulfide-linked homodimeric protein containing two 116 amino acid chains. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
IL-5 is a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. IL-5 cytokine is a main regulator of eosinopoiesis, eosinophil maturation and activation. The elevated production of this cytokine is reported to be related to asthma or hypereosinophilic syndromes. The receptor of IL-5 cytokine is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). IL-5, together with those for interleukin 4 (IL4), interleukin 13 (IL13), and CSF2, form a cytokine gene cluster on chromosome 5. IL-5, IL4, and IL13 are found to be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31.

Specifications
Specifications
Accession Number | P05113 |
For Use With (Application) | Functional Assay |
Formulation | protein with no preservative |
Gene ID (Entrez) | 3567 |
Molecular Weight (g/mol) | 26.5 kDa |
Name | Human IL-5, Animal-Free |
Quantity | 100 μg |
Source | E. coli |
Regulatory Status | RUO |
Endotoxin Concentration | <0.1 EU/ μg |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction